Ketorolac intranasal - Assertio Therapeutics
Alternative Names: Ketorolac trometamol intranasal; Ketorolac trometamol nasal spray; Ketorolac tromethamine intranasal; Ketorolac tromethamine nasal spray; ROX-828; ROX-888; SprixLatest Information Update: 17 Nov 2021
Price :
$50 *
At a glance
- Originator ROXRO PHARMA
- Developer Assertio Therapeutics; OraPharma; ROXRO PHARMA
- Class 2 ring heterocyclic compounds; Carboxylic acids; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Pyrroles; Small molecules
- Mechanism of Action Cyclo-oxygenase 1 inhibitors; Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Acute pain
- Discontinued Migraine
Most Recent Events
- 20 May 2020 Assertio Therapeutics has been merged with Zyla Life Sciences to form Assertio Therapeutics
- 27 Aug 2019 No development reported - Phase-III for Postoperative pain (In adolescents) in USA (Intranasal)
- 27 Aug 2019 No development reported - Phase-III for Postoperative pain (In children, In infants, In neonates) in Poland, USA (Intranasal)